CR20220247A - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents

Uso de reboxetina para tratar los trastornos del sistema nervioso

Info

Publication number
CR20220247A
CR20220247A CR20220247A CR20220247A CR20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A
Authority
CR
Costa Rica
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
esreboxetine
Prior art date
Application number
CR20220247A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of CR20220247A publication Critical patent/CR20220247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen los métodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administración de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) también se puede utilizar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se dan a conocer en este documento los kits que comprenden una composición farmacéutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composición farmacéutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.
CR20220247A 2019-12-03 2020-11-30 Uso de reboxetina para tratar los trastornos del sistema nervioso CR20220247A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (1)

Publication Number Publication Date
CR20220247A true CR20220247A (es) 2022-08-18

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220247A CR20220247A (es) 2019-12-03 2020-11-30 Uso de reboxetina para tratar los trastornos del sistema nervioso

Country Status (12)

Country Link
EP (1) EP4069244A4 (es)
JP (1) JP2023504685A (es)
KR (1) KR20220108122A (es)
CN (1) CN114746097A (es)
AU (2) AU2020395082A1 (es)
BR (1) BR112022010677A2 (es)
CA (1) CA3163505A1 (es)
CO (1) CO2022007507A2 (es)
CR (1) CR20220247A (es)
IL (1) IL293536A (es)
MX (1) MX2022006630A (es)
PE (1) PE20230181A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
CN1820754A (zh) * 1999-07-01 2006-08-23 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
SG11201507121RA (en) * 2013-03-13 2015-10-29 Aerial Biopharma Llc Treatment of cataplexy

Also Published As

Publication number Publication date
IL293536A (en) 2022-08-01
MX2022006630A (es) 2022-06-24
JP2023504685A (ja) 2023-02-06
CO2022007507A2 (es) 2022-06-21
CA3163505A1 (en) 2021-06-10
AU2024203676A1 (en) 2024-06-20
EP4069244A4 (en) 2023-12-20
CN114746097A (zh) 2022-07-12
EP4069244A1 (en) 2022-10-12
BR112022010677A2 (pt) 2022-08-16
AU2020395082A1 (en) 2022-06-09
KR20220108122A (ko) 2022-08-02
PE20230181A1 (es) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
ZA202304965B (en) Combination therapy for treating cancer
MX2021002322A (es) Nuevos metodos.
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
CR20220247A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
NZ761111A (en) Obinutuzumab treatment of a dlbcl patient subgroup
WO2023019095A3 (en) Momelotinib combination therapy